China: Healthcare

商业经营中，企业惯于用资产负债表衡量有形成本与收益，却很少将员工的心理健康纳入管理视野——这是一项被长期忽略的“隐形负债”。国际劳工组织（ILO）在2026年4月发布的最新全球报告显示，工作相关的心理社会风险因素每年导致超过84万人死于相关的心血管疾病和精神障碍，同时导致全ங

The US Department of Health and Human Services has launched Operation TrialBlazer to address China's growing dominance in clinical research and restore American leadership in biomedical innovation. As Chinese clinical trials now surpass US trials in both speed and volume, this comprehensive initiative aims to modernize regulatory processes, reduce administrative burdens, and reverse the trend of research investment flowing overseas.

China's National Medical Products Administration has officially implemented new drug trial data protection measures, establishing a comprehensive framework that grants varying protection periods based on innovation levels.

This China Newsletter provides an overview of key developments in the following areas...

With the core goal of achieving health equity by 2030 — meaning the elimination of health disparities to give all Chinese citizens a fair opportunity to be healthy — Healthy China 2030 stands...

In recent years, China's regulatory framework for human genetic resources has matured. Regulatory authorities have issued and updated a series of legal documents...

This article discusses the regulation of DTx products in China, the question of registration, and best practices for collecting and processing data through DTx products.

License-in/out transactions have become a key strategic approach for innovative drug and medical device (including medical aesthetics) companies to expedite the research and development of the products and expand market presence.

On February 27, 2023, the National Health Commission, together with the Ministry of Education, the Ministry of Science and Technology, and the State Administration of Traditional Chinese Medicine...